Video Resources for SARCLISA
Discover the IKEMA Trial: Experts Discuss Clinical Highlights
Case Review: Patricia, a Patient With Gain(1q21) and Progression on 1L Maintenance
Case Review: Roger, a Patient With Renal Insufficiency and Progression on 1L Maintenance
Results From IKEMA: PFS, Response Rates, MRD Negativity, and Safety
sarclisa Mechanism of Action
Join Dr Mikhael as he discusses the latest data for SARCLISA + Kd at a median follow-up of 44 months
1L=first line; Kd=carfilzomib and dexamethasone; MOA=mechanism of action; MRD=minimal (or measurable) residual disease; PFS=progression-free survival.